{
  "id": "589c4c9078275d0c4a000040",
  "type": "list",
  "question": "What are the side effects during statins administration in patients with atherosclerosis?",
  "ideal_answer": "The side effects during statins administration in patients with atherosclerosis are:\n1) Myopathy\n2) Transaminase elevations\n3) Diabetes mellitus \n4) Renal and neurologic adverse effects.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26490078",
    "http://www.ncbi.nlm.nih.gov/pubmed/25678839",
    "http://www.ncbi.nlm.nih.gov/pubmed/24840269",
    "http://www.ncbi.nlm.nih.gov/pubmed/21796961",
    "http://www.ncbi.nlm.nih.gov/pubmed/21267417",
    "http://www.ncbi.nlm.nih.gov/pubmed/12891851",
    "http://www.ncbi.nlm.nih.gov/pubmed/27878791",
    "http://www.ncbi.nlm.nih.gov/pubmed/17042673",
    "http://www.ncbi.nlm.nih.gov/pubmed/25644328",
    "http://www.ncbi.nlm.nih.gov/pubmed/19039148",
    "http://www.ncbi.nlm.nih.gov/pubmed/21972203",
    "http://www.ncbi.nlm.nih.gov/pubmed/26575138",
    "http://www.ncbi.nlm.nih.gov/pubmed/24601937",
    "http://www.ncbi.nlm.nih.gov/pubmed/25936326",
    "http://www.ncbi.nlm.nih.gov/pubmed/18585718",
    "http://www.ncbi.nlm.nih.gov/pubmed/22913216",
    "http://www.ncbi.nlm.nih.gov/pubmed/23299641",
    "http://www.ncbi.nlm.nih.gov/pubmed/24788803"
  ],
  "snippets": [
    {
      "text": "A history of side effects was reported by 40 (19.5%) of the patients, and mainly consisted of muscle complaints and gastrointestinal symptoms. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25644328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment Options for Statin-Associated Muscle Symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26490078",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower than the corresponding vascular benefits in moderate vascular risk individuals. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rosuvastatin-induced proteinuria appears to be of tubular origin, not relating to kidney injury. Rosuvastatin increases the risk of new-onset diabetes by dose-dependently impairing insulin sensitivity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24788803",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Statins are associated with myopathy, transaminase elevations, and an increased risk of incident diabetes mellitus among some patients; connections between statins and other processes, such as renal and neurologic function, have also been studied with mixed results. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24840269",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Muscle symptoms are a clinically relevant side effect of statin treatment.This review is based on pertinent publications retrieved by a selective literature search, and on the current recommendations of the European Atherosclerosis Society.At least 5% of patients taking statins have statin-associated muscle symptoms (SAMS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26575138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Better understanding of the molecular mechanisms involved in statin-induced myopathy may help identify patient groups susceptible to statins' side effects, thereby increasing their safety..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18585718",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Myopathy, Transaminase elevations, Diabetes mellitus, Renal adverse effects, Neurologic adverse effects"
}